This bill seeks to ban direct-to-consumer advertising by drug manufacturers for their prescription products. It proposes an amendment to Section 502 of the Federal Food, Drug, and Cosmetic Act, making it unlawful for manufacturers to engage in promotional communications targeting consumers for drugs approved under section 505 or licensed under section 351 of the Public Health Service Act. The legislation broadly defines "direct-to-consumer advertising" to include any marketing efforts through television, radio, print media, digital platforms, and social media . This comprehensive prohibition aims to prevent the direct marketing of prescription drugs to the public. The ban will take effect 30 days after the bill's enactment and will apply to all relevant drugs, regardless of their original approval or licensing date.